Halozyme Therapeutics Inc logo

Halozyme Therapeutics Inc

1
NAS:HALO (USA)   Ordinary Shares
$ 37.24 -0.41 (-1.09%) 08:08 PM EST
P/E:
21.78
P/B:
32.38
Market Cap:
$ 4.91B
Enterprise V:
$ 6.12B
Volume:
601.74K
Avg Vol (2M):
866.39K
Also Trade In:
Volume:
601.74K
Market Cap $:
4.91B
PE Ratio:
21.78
Avg Vol (2M):
866.39K
Enterprise Value $:
6.12B
PB Ratio:
32.38

Business Description

Halozyme Therapeutics Inc logo
Halozyme Therapeutics Inc
NAICS : 325414 SIC : 2836
ISIN : US40637H1095

Share Class Description:

HALO: Ordinary Shares
Description
Halozyme Therapeutics Inc is a biotechnology company focused on developing and commercializing novel oncology therapies. The company seeks to create therapies focused on human enzymes that alter tumors. Halozyme utilizes a strategy that focuses on developing its own proprietary products in therapeutic areas with significant unmet medical needs, with a focus on oncology, and licensing its technology to biopharmaceutical companies to collaboratively develop products. The company's operations are based in the United States, with minimal long-lived assets located internationally.
Name Current Vs Industry Vs History
Cash-To-Debt 0.23
Equity-to-Asset 0.08
Debt-to-Equity 9.91
Debt-to-EBITDA 3.85
Interest Coverage 14.49
Piotroski F-Score 6/9
0
1
2
3
4
5
6
7
8
9
Altman Z-Score 3.33
Distress
Grey
Safe
Beneish M-Score -2.48
Manipulator
Not Manipulator
WACC vs ROIC
WACC
ROIC
Name Current Vs Industry Vs History
5-Day RSI 27.27
9-Day RSI 33.49
14-Day RSI 37.16
6-1 Month Momentum % 10.53
12-1 Month Momentum % 6.89

Liquidity Ratio

Name Current Vs Industry Vs History
Current Ratio 6.58
Quick Ratio 5.44
Cash Ratio 2.99
Days Inventory 226.06
Days Sales Outstanding 87.55
Days Payable 27.96

Dividend & Buy Back

Name Current Vs Industry Vs History
3-Year Average Share Buyback Ratio 0.4
Shareholder Yield % -11.17

Financials (Next Earnings Date:2023-11-08 Est.)

HALO's 30-Y Financials
Balance Sheet Breakdown
No Enough Data
Cashflow Statement Breakdown
No Enough Data

Historical Operating Revenue by Business Segment

Historical Operating Revenue by Geographic Region

5-Step DuPont Analysis as of
No Enough Data

Guru Trades

See Details
To

Insider Trades

See Details
To

Gurus Latest Trades with NAS:HALO

No Available Data

Peter Lynch Chart

Y-axis scale:
Interactive Chart
To

Performance

Dividend
Log
Bar
To

Annualized Return %  

Symbol
1 Week
1 Month
3 Months
6 Months
YTD
1 Year
3 Years
5 Years
10 Years

Total Annual Return %  

Symbol
2023
2022
2021
2020
2019
2018
2017
2016
2015
2014

Halozyme Therapeutics Inc Executives

Details

Valuation Chart

Year:

Analyst Estimate

Key Statistics

Name Value
Revenue (TTM) (Mil $) 773.653
EPS (TTM) ($) 1.71
Beta 1.27
Volatility % 49.26
14-Day RSI 37.16
14-Day ATR ($) 1.227134
20-Day SMA ($) 39.1185
12-1 Month Momentum % 6.89
52-Week Range ($) 29.85 - 59.46
Shares Outstanding (Mil) 131.92

Piotroski F-Score Details

Year:
Component Result
Piotroski F-Score 6
Positive ROA
Positive CFROA
Higher ROA yoy
CFROA > ROA
Lower Leverage yoy
Higher Current Ratio yoy
Less Shares Outstanding yoy
Higher Gross Margin yoy
Higher Asset Turnover yoy

Halozyme Therapeutics Inc Filings

Filing Date Document Date Form
No Filing Data

Halozyme Therapeutics Inc Stock Events

Event Date Price($)
No Event Data

Halozyme Therapeutics Inc Frequently Asked Questions

What is Halozyme Therapeutics Inc(HALO)'s stock price today?
The current price of HALO is $37.24. The 52 week high of HALO is $59.46 and 52 week low is $29.85.
When is next earnings date of Halozyme Therapeutics Inc(HALO)?
The next earnings date of Halozyme Therapeutics Inc(HALO) is 2023-11-08 Est..
Does Halozyme Therapeutics Inc(HALO) pay dividends? If so, how much?
Halozyme Therapeutics Inc(HALO) does not pay dividend.

Press Release

Subject Date
No Press Release

Headlines

See More
  • 1
No news.
  • 1